Lilly,
Boehringer diabetes drug cuts heart attack, stroke risk in trial
(Reuters) - A new
diabetes pill from Eli Lilly and Co and
Boehringer Ingelheim cut
risk of
heart attack, stroke and death in a closely watched study, the first glucose-lowering
drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.
